DK1855657T3 - Doseringsform indeholdende oxycodon og naloxon - Google Patents

Doseringsform indeholdende oxycodon og naloxon

Info

Publication number: DK1855657T3
Authority: DK; Denmark
Prior art keywords: naloxone; dosage form; sub; form containing; containing oxycodone
Prior art date: 2005-02-28

Application number

DK06708567.0T

Other languages

English (en)

Inventor

Petra Leyendecker

Michael Hopp

Kevin Smith

Original Assignee

Euro Celtique Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-28

Filing date

2006-02-28

Publication date

2011-10-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34933990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1855657(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-02-28 Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa

2011-10-17 Application granted granted Critical

2011-10-17 Publication of DK1855657T3 publication Critical patent/DK1855657T3/da

Links

BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 title abstract 2
239000002552 dosage form Substances 0.000 title abstract 2
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 title abstract 2
229960004127 naloxone Drugs 0.000 title abstract 2
229960002085 oxycodone Drugs 0.000 title abstract 2
230000000202 analgesic effect Effects 0.000 abstract 1
230000003871 intestinal function Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

DK06708567.0T 2005-02-28 2006-02-28 Doseringsform indeholdende oxycodon og naloxon DK1855657T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP05004377A EP1695700A1 (en)	2005-02-28	2005-02-28	Dosage form containing oxycodone and naloxone
PCT/EP2006/060341 WO2006089973A2 (en)	2005-02-28	2006-02-28	Dosage form containing oxycodone and naloxone

Publications (1)

Publication Number	Publication Date
DK1855657T3 true DK1855657T3 (da)	2011-10-17

Family

ID=34933990

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK06708567.0T DK1855657T3 (da)	2005-02-28	2006-02-28	Doseringsform indeholdende oxycodon og naloxon
DK200700248U DK200700248U3 (da)	2005-02-28	2007-09-27	Doseringsform indeholdende oxycodon og naloxon

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK200700248U DK200700248U3 (da)	2005-02-28	2007-09-27	Doseringsform indeholdende oxycodon og naloxon

Country Status (26)

Country	Link
US (5)	US20080145429A1 (da)
EP (5)	EP1695700A1 (da)
JP (2)	JP2008531650A (da)
KR (1)	KR20070107805A (da)
CN (2)	CN104027297A (da)
AT (1)	ATE517611T1 (da)
AU (2)	AU2006217870B2 (da)
BR (1)	BRPI0607975A2 (da)
CA (3)	CA2768075A1 (da)
CY (1)	CY1111967T1 (da)
DE (2)	DE202006020095U1 (da)
DK (2)	DK1855657T3 (da)
ES (1)	ES2370409T3 (da)
FI (1)	FI7750U1 (da)
HR (1)	HRP20110775T1 (da)
IL (2)	IL185514A0 (da)
ME (1)	ME01262B (da)
MX (1)	MX2007010494A (da)
NZ (1)	NZ588875A (da)
PL (1)	PL1855657T3 (da)
PT (1)	PT1855657E (da)
RS (1)	RS51984B (da)
RU (1)	RU2428985C2 (da)
SI (1)	SI1855657T1 (da)
UA (1)	UA93543C2 (da)
WO (1)	WO2006089973A2 (da)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1041987B1 (en)	1997-12-22	2006-04-19	Euro-Celtique S.A.	Pharmaceutical oral dosage form comprising a combination of an opioid agonist and naltrexone
US6375957B1 (en)	1997-12-22	2002-04-23	Euro-Celtique, S.A.	Opioid agonist/opioid antagonist/acetaminophen combinations
EP1387673B1 (en)	2001-05-11	2010-12-29	Endo Pharmaceuticals Inc.	Abuse-resistant controlled-release opioid dosage form
ES2654819T3 (es)	2001-10-18	2018-02-15	Nektar Therapeutics	Conjugados poliméricos de antagonistas de opioides
HUE032656T2 (en) *	2002-04-05	2017-10-30	Euro Celtique Sa	Pharmaceutical composition containing oxicodone and naloxone
US7776314B2 (en)	2002-06-17	2010-08-17	Grunenthal Gmbh	Abuse-proofed dosage system
DE10336400A1 (de)	2003-08-06	2005-03-24	Grünenthal GmbH	Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de)	2003-12-24	2005-09-29	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en)	2003-08-06	2007-03-01	Elisabeth Arkenau-Maric	Abuse-proofed dosage form
DE102005005446A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Bruchfeste Darreichungsformen mit retardierter Freisetzung
EP1604666A1 (en)	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1604667A1 (en) *	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioids for the treatment of the restless leg syndrome
DE102004032049A1 (de)	2004-07-01	2006-01-19	Grünenthal GmbH	Gegen Missbrauch gesicherte, orale Darreichungsform
GEP20105052B (en) *	2005-01-28	2010-07-26	Euro Celtique Sa	Alcohol resistant dosage forms
DE102005005449A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1702558A1 (en)	2005-02-28	2006-09-20	Euro-Celtique S.A.	Method and device for the assessment of bowel function
EP1695700A1 (en) *	2005-02-28	2006-08-30	Euro-Celtique S.A.	Dosage form containing oxycodone and naloxone
DE202006018609U1 (de) *	2006-08-29	2007-05-16	Euro-Celtique S.A.	Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung
JP2010509227A (ja) *	2006-11-07	2010-03-25	ネクターセラピューティックスエイエル，コーポレイション	オピオイド作動薬およびオピオイド拮抗薬の用量形態および同時投与
US20090004231A1 (en)	2007-06-30	2009-01-01	Popp Shane M	Pharmaceutical dosage forms fabricated with nanomaterials for quality monitoring
EP2042176A1 (en) *	2007-09-26	2009-04-01	Euro-Celtique S.A.	Use of a combination of an opioid agonist and an opioid antagonist for the treatment of Crohn's disease
US8486448B2 (en)	2007-12-17	2013-07-16	Paladin Labs Inc.	Misuse preventative, controlled release formulation
KR101616246B1 (ko)	2008-01-25	2016-05-02	그뤼넨탈 게엠베하	약제학적 투여형
AU2009243681B2 (en)	2008-05-09	2013-12-19	Grunenthal Gmbh	Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
EP2317991B1 (en) *	2008-07-07	2017-05-03	Euro-Celtique S.A.	Use of opioid antagonists for treating urinary retention
AU2009327312A1 (en)	2008-12-16	2011-08-04	Labopharm Europe Limited	Misuse preventative, controlled release formulation
SG174286A1 (en) *	2009-03-10	2011-10-28	Euro Celtique Sa	Immediate release pharmaceutical compositions comprising oxycodone and naloxone
WO2011009602A1 (en)	2009-07-22	2011-01-27	Grünenthal GmbH	Hot-melt extruded controlled release dosage form
TWI473628B (zh)	2009-07-22	2015-02-21		用於對氧化敏感之類鴉片藥劑之抗破壞劑型
US8475832B2 (en)	2009-08-07	2013-07-02	Rb Pharmaceuticals Limited	Sublingual and buccal film compositions
US9579285B2 (en)	2010-02-03	2017-02-28	Gruenenthal Gmbh	Preparation of a powdery pharmaceutical composition by means of an extruder
AU2011252039B2 (en)	2010-05-10	2014-06-12	Euro-Celtique S.A.	Pharmaceutical compositions comprising hydromorphone and naloxone
CA2798884C (en)	2010-05-10	2016-09-13	Euro-Celtique S.A.	Manufacturing of active-free granules and tablets comprising the same
CN103002881B (zh)	2010-05-10	2015-09-02	欧洲凯尔特公司	载有活性剂的颗粒与额外活性剂的组合
EP2603205B1 (en) *	2010-08-13	2018-10-03	Euro-Celtique S.A.	Use of binders for manufacturing storage stable formulations
CA2808219C (en)	2010-09-02	2019-05-14	Gruenenthal Gmbh	Tamper resistant dosage form comprising inorganic salt
WO2012028318A1 (en)	2010-09-02	2012-03-08	Grünenthal GmbH	Tamper resistant dosage form comprising an anionic polymer
AR084620A1 (es) *	2010-12-28	2013-05-29	Euro Celtique Sa	Una combinacion de un agonista opiaceo y un antagonista opiaceo en el tratamiento de la enfermedad de parkinson
AU2012289764B2 (en)	2011-07-29	2017-03-02	Grünenthal GmbH	Tamper-resistant tablet providing immediate drug release
ES2648129T3 (es)	2011-07-29	2017-12-28	Grünenthal GmbH	Pastilla a prueba de manipulación que proporciona una liberación inmediata de un medicamento
US20130225697A1 (en)	2012-02-28	2013-08-29	Grunenthal Gmbh	Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
KR102196741B1 (ko)	2012-04-17	2020-12-30	퍼듀 퍼머 엘피	오피오이드-유도 유해 약역학 반응을 치료하기 위한 시스템 및 방법
PL2838512T3 (pl)	2012-04-18	2018-12-31	Grünenthal GmbH	Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en)	2012-05-11	2018-09-04	Gruenenthal Gmbh	Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AU2014273227B2 (en)	2013-05-29	2019-08-15	Grunenthal Gmbh	Tamper-resistant dosage form containing one or more particles
JP6466417B2 (ja)	2013-05-29	2019-02-06	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
JP6449871B2 (ja)	2013-07-12	2019-01-09	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	エチレン−酢酸ビニルポリマーを含有する改変防止剤形
JP2016525138A (ja)	2013-07-23	2016-08-22	ユーロ−セルティークエス．エイ．	疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
WO2015071380A1 (en)	2013-11-13	2015-05-21	Euro-Celtique S.A.	Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
EP3073994A1 (en)	2013-11-26	2016-10-05	Grünenthal GmbH	Preparation of a powdery pharmaceutical composition by means of cryo-milling
US9192570B2 (en)	2013-12-20	2015-11-24	AntiOP, Inc.	Intranasal naloxone compositions and methods of making and using same
US10085937B2 (en)	2014-03-14	2018-10-02	Adapt Pharma Limited	Nasal drug products and methods of their use
US9480644B2 (en)	2014-03-14	2016-11-01	Opiant Pharmaceuticals, Inc.	Nasal drug products and methods of their use
US9561177B2 (en)	2014-03-14	2017-02-07	Adapt Pharma Limited	Nasal drug products and methods of their use
HK1231370A1 (zh)	2014-03-14	2017-12-22	欧皮安特制药有限公司	鼻用药物产品及其使用方法
EP3142646A1 (en)	2014-05-12	2017-03-22	Grünenthal GmbH	Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru)	2014-05-26	2017-05-31	Грюненталь Гмбх	Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
EP3174534A1 (en) *	2014-08-01	2017-06-07	KRKA, d.d., Novo mesto	Pharmaceutical formulation comprising an opioid agonist and an opioid antagonist prepared by melt granulation using lipid esters
US9849124B2 (en)	2014-10-17	2017-12-26	Purdue Pharma L.P.	Systems and methods for treating an opioid-induced adverse pharmacodynamic response
US20160256451A1 (en) *	2015-03-06	2016-09-08	Develco Pharma Schweiz Ag	Dosage of naloxone
US20160256453A1 (en) *	2015-03-06	2016-09-08	Develco Pharma Schweiz Ag	Opioid receptor antagonist for use in treating patients with severe constipation induced by high opiate dosage regimen
BR112017021475A2 (pt)	2015-04-24	2018-07-10	Gruenenthal Gmbh	forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
WO2016193456A2 (en) *	2015-06-03	2016-12-08	Develco Pharma Schweiz Ag	Opioid receptor antagonist for use in treating patients with severe constipation
WO2017042325A1 (en)	2015-09-10	2017-03-16	Grünenthal GmbH	Protecting oral overdose with abuse deterrent immediate release formulations
US9861629B1 (en)	2015-10-07	2018-01-09	Banner Life Sciences Llc	Opioid abuse deterrent dosage forms
US10335405B1 (en)	2016-05-04	2019-07-02	Patheon Softgels, Inc.	Non-burst releasing pharmaceutical composition
US10335375B2 (en)	2017-05-30	2019-07-02	Patheon Softgels, Inc.	Anti-overingestion abuse deterrent compositions
JP2020526500A (ja)	2017-06-30	2020-08-31	パーデュー、ファーマ、リミテッド、パートナーシップ	治療方法及びその剤形
US12475984B2 (en) *	2019-08-05	2025-11-18	Rxassurance Corporation	Techniques for providing interactive clinical decision support for drug dosage reduction
US20240131022A1 (en) *	2022-03-11	2024-04-25	John Abernethy	Opioid overdose reversal mixtures

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3173876A (en) *	1960-05-27	1965-03-16	John C Zobrist	Cleaning methods and compositions
NL271831A (da) *	1960-11-29
US3276586A (en) *	1963-08-30	1966-10-04	Rosaen Filter Co	Indicating means for fluid filters
NL6714885A (da) *	1967-11-02	1969-05-06
US3541006A (en) *	1968-07-03	1970-11-17	Amicon Corp	Ultrafiltration process
US3773955A (en)	1970-08-03	1973-11-20	Bristol Myers Co	Analgetic compositions
FR2183546B1 (da) *	1972-05-10	1975-06-20	Servier Lab
US3845770A (en) *	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en) *	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US3916889A (en) *	1973-09-28	1975-11-04	Sandoz Ag	Patient ventilator apparatus
US3966940A (en) *	1973-11-09	1976-06-29	Bristol-Myers Company	Analgetic compositions
GB1478759A (en) *	1974-11-18	1977-07-06	Alza Corp	Process for forming outlet passageways in pills using a laser
US3966040A (en) *	1975-03-05	1976-06-29	Hazelwood John E	Combined vibratory feeder drive unit, vibratory feeder bowl, and parts separator
US4077407A (en) *	1975-11-24	1978-03-07	Alza Corporation	Osmotic devices having composite walls
US4126684A (en) *	1976-02-11	1978-11-21	Ciba-Geigy Corporation	4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4063064A (en) *	1976-02-23	1977-12-13	Coherent Radiation	Apparatus for tracking moving workpiece by a laser beam
US4200098A (en) *	1978-10-23	1980-04-29	Alza Corporation	Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) *	1978-10-23	1981-08-25	Alza Corporation	Process for manufacturing device with dispersion zone
US4457933A (en) *	1980-01-24	1984-07-03	Bristol-Myers Company	Prevention of analgesic abuse
GB8332556D0 (en)	1983-12-06	1984-01-11	Reckitt & Colmann Prod Ltd	Analgesic compositions
US4668685A (en) *	1984-07-05	1987-05-26	E.I. Du Pont De Nemours And Company	Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
US4769372A (en) *	1986-06-18	1988-09-06	The Rockefeller University	Method of treating patients suffering from chronic pain or chronic cough
US4861598A (en) *	1986-07-18	1989-08-29	Euroceltique, S.A.	Controlled release bases for pharmaceuticals
DE3812567A1 (de) *	1988-04-15	1989-10-26	Basf Ag	Verfahren zur herstellung pharmazeutischer mischungen
EP0352361A1 (en)	1988-07-29	1990-01-31	The Rockefeller University	Method of treating patients suffering from chronic pain or chronic cough
US5236714A (en) *	1988-11-01	1993-08-17	Alza Corporation	Abusable substance dosage form having reduced abuse potential
US5266331A (en) *	1991-11-27	1993-11-30	Euroceltique, S.A.	Controlled release oxycodone compositions
US5656295A (en) *	1991-11-27	1997-08-12	Euro-Celtique, S.A.	Controlled release oxycodone compositions
US5968551A (en) *	1991-12-24	1999-10-19	Purdue Pharma L.P.	Orally administrable opioid formulations having extended duration of effect
US5273760A (en) *	1991-12-24	1993-12-28	Euroceltigue, S.A.	Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5286493A (en) *	1992-01-27	1994-02-15	Euroceltique, S.A.	Stabilized controlled release formulations having acrylic polymer coating
US5478577A (en) *	1993-11-23	1995-12-26	Euroceltique, S.A.	Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5472712A (en) *	1991-12-24	1995-12-05	Euroceltique, S.A.	Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5681585A (en) *	1991-12-24	1997-10-28	Euro-Celtique, S.A.	Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5324351A (en) *	1992-08-13	1994-06-28	Euroceltique	Aqueous dispersions of zein and preparation thereof
NZ260408A (en) *	1993-05-10	1996-05-28	Euro Celtique Sa	Controlled release preparation comprising tramadol
IL110014A (en) *	1993-07-01	1999-11-30	Euro Celtique Sa	Solid controlled-release oral dosage forms of opioid analgesics
DE4325465B4 (de) *	1993-07-29	2004-03-04	Zenz, Michael, Prof. Dr.med.	Orales pharmazeutisches Präparat für die Schmerztherapie
US5411745A (en) *	1994-05-25	1995-05-02	Euro-Celtique, S.A.	Powder-layered morphine sulfate formulations
US5866154A (en) *	1994-10-07	1999-02-02	The Dupont Merck Pharmaceutical Company	Stabilized naloxone formulations
US5965161A (en) *	1994-11-04	1999-10-12	Euro-Celtique, S.A.	Extruded multi-particulates
US5865161A (en) *	1995-01-04	1999-02-02	Bruce; Norman R.	Baseball pitching device
US20020006964A1 (en) *	1995-05-16	2002-01-17	Young James W.	Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
DE19651551C2 (de)	1996-12-11	2000-02-03	Klinge Co Chem Pharm Fab	Opioidantagonisthaltige galenische Formulierung
US6207142B1 (en) *	1997-04-14	2001-03-27	Janssen Pharmaceutica N.V.	Compositions containing an antifungal and a cationic agent
CA2270975C (en) *	1997-07-02	2003-04-01	Euro-Celtique, S.A.	Stabilized sustained release tramadol formulations
EP1041987B1 (en) *	1997-12-22	2006-04-19	Euro-Celtique S.A.	Pharmaceutical oral dosage form comprising a combination of an opioid agonist and naltrexone
EP1041988A4 (en) *	1997-12-22	2002-03-13	Euro Celtique Sa	METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS
JP2002507562A (ja) *	1998-03-27	2002-03-12	ファルマシア・アンド・アップジョン・カンパニー	レストレスレッグ症候群の治療におけるカベルゴリンの使用
US20030178031A1 (en) *	1999-05-07	2003-09-25	Du Pen, Inc.	Method for cancer pain treatment
WO2000078022A1 (en) *	1999-06-11	2000-12-21	Telstra New Wave Pty Ltd	A method of developing an interactive system
US20030118641A1 (en) *	2000-07-27	2003-06-26	Roxane Laboratories, Inc.	Abuse-resistant sustained-release opioid formulation
DE19938823A1 (de) *	1999-08-19	2001-02-22	Boehringer Ingelheim Pharma	Medikamentöse Behandlung des Restless Leg Syndroms
US6258042B1 (en)	1999-09-17	2001-07-10	James S. Factor	Visual analog scale and method of use for the diagnosis and/or treatment of physical pain
EP2092936B1 (en) *	2000-02-08	2013-03-20	Euro-Celtique S.A.	Tamper-resistant oral opioid agonist formulations
US6716449B2 (en) *	2000-02-08	2004-04-06	Euro-Celtique S.A.	Controlled-release compositions containing opioid agonist and antagonist
US7223421B2 (en) *	2000-06-30	2007-05-29	Mcneil-Ppc, Inc.	Teste masked pharmaceutical particles
AR031152A1 (es) *	2000-10-31	2003-09-10	Upjohn Co	Tratamientos nuevos para el sindrome de piernas inquietas
SK12822003A3 (sk) *	2001-04-19	2004-04-06	Warner - Lambert Company Llc	Fúzne bicyklické alebo tricyklické aminokyseliny
UA81224C2 (uk) *	2001-05-02	2007-12-25	Euro Celtic S A	Дозована форма оксикодону та її застосування
EP1387673B1 (en) *	2001-05-11	2010-12-29	Endo Pharmaceuticals Inc.	Abuse-resistant controlled-release opioid dosage form
CA2446738C (en) *	2001-05-11	2012-05-29	Endo Pharmaceuticals, Inc.	Abuse-resistant opioid dosage form
SI1416842T1 (sl) *	2001-07-18	2009-06-30	Euro Celtique Sa	Farmacevtske kombinacije oksikodona in naloksona
US7332182B2 (en) *	2001-08-06	2008-02-19	Purdue Pharma L.P.	Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
IL160222A0 (en) *	2001-08-06	2004-07-25	Euro Celtique Sa	Opioid agonist formulations with releasable and sequestered antagonist
US20030044458A1 (en) *	2001-08-06	2003-03-06	Curtis Wright	Oral dosage form comprising a therapeutic agent and an adverse-effect agent
BR0212019A (pt) *	2001-08-06	2005-08-09	Euro Celtique Sa	Formas de dosagem, métodos para o tratamento da dor, métodos de preparação de uma forma de dosagem e métodos para impedir o abuso de uma forma de dosagem
JP2005512965A (ja) *	2001-09-24	2005-05-12	オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド	不穏四肢症候群および定期的四肢運動障害の処置に有用な抗痙攣誘導体
WO2003073937A1 (en)	2002-03-06	2003-09-12	Euro-Celtique S.A.	Analog scale for measuring pain
HUE032656T2 (en) *	2002-04-05	2017-10-30	Euro Celtique Sa	Pharmaceutical composition containing oxicodone and naloxone
US20030191147A1 (en) *	2002-04-09	2003-10-09	Barry Sherman	Opioid antagonist compositions and dosage forms
JP4694207B2 (ja) *	2002-07-05	2011-06-08	コルジウムファーマシューティカル，インコーポレイテッド	オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物
MY135852A (en) *	2003-04-21	2008-07-31	Euro Celtique Sa	Pharmaceutical products
US7700626B2 (en) *	2004-06-04	2010-04-20	Adolor Corporation	Compositions containing opioid antagonists
EP1604666A1 (en) *	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1695700A1 (en)	2005-02-28	2006-08-30	Euro-Celtique S.A.	Dosage form containing oxycodone and naloxone

2005
- 2005-02-28 EP EP05004377A patent/EP1695700A1/en not_active Withdrawn
2006
- 2006-02-28 UA UAA200811581A patent/UA93543C2/ru unknown
- 2006-02-28 SI SI200631121T patent/SI1855657T1/sl unknown
- 2006-02-28 HR HR20110775T patent/HRP20110775T1/hr unknown
- 2006-02-28 NZ NZ588875A patent/NZ588875A/en not_active IP Right Cessation
- 2006-02-28 BR BRPI0607975-0A patent/BRPI0607975A2/pt not_active Application Discontinuation
- 2006-02-28 RU RU2007135991/15A patent/RU2428985C2/ru not_active IP Right Cessation
- 2006-02-28 ME MEP-2011-173A patent/ME01262B/me unknown
- 2006-02-28 CA CA2768075A patent/CA2768075A1/en not_active Abandoned
- 2006-02-28 MX MX2007010494A patent/MX2007010494A/es active IP Right Grant
- 2006-02-28 JP JP2007557493A patent/JP2008531650A/ja not_active Withdrawn
- 2006-02-28 AT AT06708567T patent/ATE517611T1/de active
- 2006-02-28 EP EP19167974.5A patent/EP3578173B1/en not_active Expired - Lifetime
- 2006-02-28 EP EP06708567A patent/EP1855657B1/en not_active Revoked
- 2006-02-28 EP EP10176716A patent/EP2258353A3/en not_active Withdrawn
- 2006-02-28 ES ES06708567T patent/ES2370409T3/es not_active Expired - Lifetime
- 2006-02-28 DE DE202006020095U patent/DE202006020095U1/de not_active Expired - Lifetime
- 2006-02-28 CN CN201410239260.4A patent/CN104027297A/zh active Pending
- 2006-02-28 EP EP15180143.8A patent/EP2962686B1/en not_active Revoked
- 2006-02-28 DK DK06708567.0T patent/DK1855657T3/da active
- 2006-02-28 CA CA2960011A patent/CA2960011A1/en not_active Abandoned
- 2006-02-28 PL PL06708567T patent/PL1855657T3/pl unknown
- 2006-02-28 CN CNA2006800059691A patent/CN101128191A/zh not_active Withdrawn
- 2006-02-28 AU AU2006217870A patent/AU2006217870B2/en not_active Expired
- 2006-02-28 WO PCT/EP2006/060341 patent/WO2006089973A2/en not_active Ceased
- 2006-02-28 DE DE19167974.5T patent/DE19167974T1/de active Pending
- 2006-02-28 US US11/885,288 patent/US20080145429A1/en not_active Abandoned
- 2006-02-28 KR KR1020077022380A patent/KR20070107805A/ko not_active Ceased
- 2006-02-28 CA CA2599156A patent/CA2599156C/en not_active Expired - Lifetime
- 2006-02-28 PT PT06708567T patent/PT1855657E/pt unknown
- 2006-02-28 RS RS20110458A patent/RS51984B/sr unknown
2007
- 2007-04-13 FI FI20070153U patent/FI7750U1/fi not_active IP Right Cessation
- 2007-08-26 IL IL185514A patent/IL185514A0/en unknown
- 2007-09-27 DK DK200700248U patent/DK200700248U3/da not_active IP Right Cessation
2009
- 2009-01-15 IL IL196539A patent/IL196539A0/en unknown
- 2009-03-13 AU AU2009201019A patent/AU2009201019B2/en not_active Ceased
2010
- 2010-11-12 US US12/945,164 patent/US20110172259A1/en not_active Abandoned
2011
- 2011-10-25 CY CY20111101011T patent/CY1111967T1/el unknown
- 2011-12-16 US US13/329,218 patent/US20120225901A1/en not_active Abandoned
2013
- 2013-10-02 US US14/044,175 patent/US20140031382A1/en not_active Abandoned
2014
- 2014-04-24 JP JP2014090036A patent/JP6235962B2/ja not_active Expired - Lifetime
2017
- 2017-03-23 US US15/467,877 patent/US20180008593A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2014169303A (ja)	2014-09-18
FIU20070153U0 (fi)	2007-04-13
CA2599156A1 (en)	2006-08-31
JP2008531650A (ja)	2008-08-14
SI1855657T1 (sl)	2011-11-30
AU2009201019A1 (en)	2009-04-02
BRPI0607975A2 (pt)	2009-10-27
FI7750U1 (fi)	2008-01-22
ES2370409T3 (es)	2011-12-15
EP1855657A2 (en)	2007-11-21
RU2007135991A (ru)	2009-04-10
US20180008593A1 (en)	2018-01-11
CN101128191A (zh)	2008-02-20
HRP20110775T1 (hr)	2011-11-30
MX2007010494A (es)	2008-01-16
CN104027297A (zh)	2014-09-10
DK200700248U1 (da)	2007-12-14
DE202006020095U1 (de)	2007-11-08
JP6235962B2 (ja)	2017-11-22
RU2428985C2 (ru)	2011-09-20
WO2006089973A2 (en)	2006-08-31
EP3578173B1 (en)	2022-10-26
US20080145429A1 (en)	2008-06-19
DE19167974T1 (de)	2021-12-30
IL196539A0 (en)	2011-07-31
CY1111967T1 (el)	2015-11-04
PL1855657T3 (pl)	2012-03-30
WO2006089973A3 (en)	2006-12-28
CA2768075A1 (en)	2006-08-31
EP2258353A3 (en)	2012-05-09
US20140031382A1 (en)	2014-01-30
CA2599156C (en)	2012-05-01
HK1111604A1 (en)	2008-08-15
IL185514A0 (en)	2008-01-06
EP2962686A1 (en)	2016-01-06
EP2962686B1 (en)	2019-04-10
EP3578173A1 (en)	2019-12-11
AU2009201019B2 (en)	2011-05-26
PT1855657E (pt)	2011-10-31
CA2960011A1 (en)	2006-08-31
ATE517611T1 (de)	2011-08-15
US20120225901A1 (en)	2012-09-06
US20110172259A1 (en)	2011-07-14
EP1855657B1 (en)	2011-07-27
UA93543C2 (ru)	2011-02-25
AU2006217870A1 (en)	2006-08-31
EP2258353A2 (en)	2010-12-08
AU2006217870B2 (en)	2008-12-18
NZ588875A (en)	2012-02-24
EP1695700A1 (en)	2006-08-30
ME01262B (me)	2013-06-20
RS51984B (sr)	2012-02-29
DK200700248U3 (da)	2008-02-08
KR20070107805A (ko)	2007-11-07

Publication	Publication Date	Title
DK1855657T3 (da)	2011-10-17	Doseringsform indeholdende oxycodon og naloxon
ZA200704130B (en)	2008-08-27	Protassium salt of an HIV integrase inhibitor
WO2007087395A3 (en)	2007-11-08	UNSATURATED mTOR INHIBITORS
PT1940839E (pt)	2013-10-10	Inibidores de piridopirimidinona pi3k alfa
WO2009152356A3 (en)	2010-02-25	Compounds and compositions useful for the treatment of malaria
SG179418A1 (en)	2012-04-27	Inhibitors of the hedgehog pathway
WO2009156462A3 (en)	2010-05-27	Organic compounds
UA89220C2 (ru)	2010-01-11	Способ лечения вич/спида путем приема без пищи или в условиях голодания твердого фармацевтического дозированного состава ингибитора вич-протеазы
TW200833370A (en)	2008-08-16	Pharmaceutical composition containing low substituted hydroxypropylcellulose
WO2007115305A3 (en)	2008-04-24	Oral dosage forms including an antiplatelet agent and an acid inhibitor
MXPA05012463A (es)	2006-01-30	Combinaciones farmaceuticas de un inhibidor de bomba protonica y un compuesto que modifica la motilidad gastrointestinal.
NO20064555L (no)	2006-12-04	HIV-integraseinhibitorer.
IL193252A0 (en)	2009-02-11	N-hydroxyacrylamide compounds
EP1862070A3 (en)	2011-07-27	Microbicidal composition
AP2005003451A0 (en)	2005-12-31	HIV integrase inhibitors.
TW200738699A (en)	2007-10-16	4-Substituted pyrazoline compounds, their preparation and use as medicaments
WO2007130507A3 (en)	2008-01-17	Acute pain medications based on fast acting diclofenac-opioid combinations
WO2008139952A1 (ja)	2008-11-20	微小管破壊剤及びそれを含有する癌細胞増殖抑制剤
WO2007115287A3 (en)	2007-11-29	Combination of organic compounds
GB2421245B (en)	2008-11-12	Low Dosage Naphthenate Inhibitors
WO2006055663A3 (en)	2006-09-14	The use of novel antibacterial compounds
WO2007139948A3 (en)	2008-01-24	Imidazoazepinone compounds
WO2006097472A3 (en)	2007-09-07	Novel inhibitors of glutathione-s-transferase
GB0618870D0 (en)	2006-11-01	Organic compounds
TW200505868A (en)	2005-02-16	New synerglstic combinations